Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
DENVER, Nov. 16, 2020 /PRNewswire/ -- Theralink Technologies (OTC: OBMP) ("Theralink" or the "Company"), a precision oncology molecular profiling company with a novel phosphoprotein-based laboratory developed test (LDT), today announced its partnership with Perthera, a market leader in Precision Oncology technology and services. The alliance will facilitate and accelerate access to Theralink's 32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients.
Theralink will be launching its Reverse Phase Protein Array (RPPA) based LDT this year. This unique assay is the world's only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Together, Theralink and Perthera will collaborate to provide the Theralink assay results to oncologists in an easy to interpret, "powered by Perthera" report for potentially improved insights into therapeutic options for the patient's care plan.
Through this partnership, Perthera will develop and manage Theralink's observational registry trial, TRACE (Theralink Registry to Assess Comprehensive Effectiveness). Perthera will utilize its Precision Oncology Platform, and serve as a Clinical Research Organization (CRO), to establish and launch the participation of Oncology practices and hospitals in the observational study throughout the US, implement the TRACE protocol, and assist in the enrollment of patients. Theralink will also utilize Perthera's Therapeutic Intelligence Engine™ to deliver a highly differentiated clinical report for physicians to gain clinical decision support more effectively from the innovative Theralink assay.
Theralink has established TRACE to determine clinical utility using three indicators: Frequency of Actionable Data, Therapy Selection based upon the Theralink Assay, and Outcomes. Demonstrating clinical utility will allow Theralink to apply for a reimbursement code to potentially obtain full reimbursement from 3rd party payors for patients. In TRACE, the Theralink assay will be assessed alongside commercially available NGS-based genomic assay results. In addition, all patients enrolled in TRACE will have access to Perthera's Precision Medicine Platform and proprietary report.
"Partnering with Perthera, whose Platform has been utilized by over 250 cancer care sites, provides us with an opportunity to have our Theralink Assay reach thousands of breast cancer patients in the U.S. and the oncologists who treat them. Further, the expert team at Perthera has the proven ability to deploy their established Precision Oncology Platform to develop and manage the TRACE program to comprehensively assess the clinical utility of the Theralink assay and to advance our efforts for reimbursement from the payor community," said Mick Ruxin, M.D., President and CEO of Theralink Technologies, Inc. "Together, we may reveal therapeutic options for oncologists, and in turn, potentially provide better outcomes for breast cancer patients."
"We are excited to partner with Theralink and use our Platform to drive the TRACE program as we galvanize the clinical utility of their unique RPPA assay for patients, physicians and payers. The Program will also capitalize upon Perthera's outcomes capture capabilities by integrating the world's first phosphoprotein assay within Perthera's proprietary computational engine with AI to deliver precisely ranked therapeutic options, proven to advance patient outcomes. Initially targeting those who suffer from breast cancer, and expanding the Program to additional cancer types, this unique combination of RPPA technology, medicine, science and big data may help dramatically improve outcomes for patients. We look forward to advancing our integrated partnership and driving Theralink's innovative testing across the nation," said Gary Gregory, CEO of Perthera.
About the RPPA phosphoprotein and protein panel LDT
About Theralink Technologies, Inc.
View original content:http://www.prnewswire.com/news-releases/theralink-technologies-announces-partnership-with-perthera-to-facilitate-and-accelerate-access-to-its-unique-phosphoprotein-and-drug-target-activation-testing-in-the-us-301173523.html
SOURCE Theralink Technologies